All In Biotech

NDA 208081 · Biofrontera

Ameluz

Aminolevulinic Acid Hydrochloride · Topical

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

May 10, 2016

Approved uses

3

Original approval plus efficacy supplements

Registered trials

200

40 Phase 3, 19 recruiting

FAERS reports

292

112 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 13, 2026.

1. INDICATIONS AND USAGE AMELUZ, in combination with photodynamic therapy (PDT) using BF-RhodoLED ® or RhodoLED ® XL lamp, a narrowband, red light illumination source, is indicated for: lesion-directed and field-directed treatment of actinic keratoses (AKs) of mild-to-moderate severity on the face and scalp in adults. the treatment of superficial basal cell carcinoma (sBCC) in adults. AMELUZ, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED or RhodoLED XL lamp, is indicated for: lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp in adults ( 1 ). the treatment of superficial basal cell carcinoma (sBCC) in adults ( 1 ).

Mechanism: Photoactivation following topical application of AMELUZ occurs when aminolevulinic acid (prodrug) is metabolized to protoporphyrin IX (PpIX), a photoactive compound which accumulates in the skin. When exposed to red light of a suitable wavelength and energy, PpIX is activated resulting in an excited state of porphyrin molecules. In the presence of oxygen, reactive oxygen species are formed which causes damage to cellular components, and eventually destroys the cells. AMELUZ photodynamic therapy of AK and sBCC lesions utilizes photoactivation of topically applied AMELUZ resulting from...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AMELUZ · AMINOLEVULINIC ACID HYDROCHLORIDE 10% · GEL, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aminolevulinic Acid" as an intervention, any sponsor and status, largest first.

All 200 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use74
  • application site pain59
  • application site erythema50
  • hypotension30
  • drug ineffective17
  • application site swelling16
  • product odour abnormal15
  • pain12
  • product colour issue11
  • application site pustules10
  • application site vesicles10
  • erythema10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20142
20152
20162
201725
201826
201924
202018
202130
202230
202342
202435
202532
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Ameluz (Aminolevulinic Acid HCL) · HCPCS J7345

2024 spending

$16.0M

Beneficiaries

30,905

48,458 claims

Per beneficiary

$518

2024 ASP limit $1.70 per unit

View as table
YearSpending
2020$9,217,456
2021$10,718,886
2022$12,034,195
2023$13,853,216
2024$16,012,799

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 556 on PubMed

Sponsor: Biofrontera

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.